PSI-6206 (also known as GS331007 and RO-2433), a deaminated derivative of PSI-6130, is a novel, potent and selective inhibitor of HCV NS5B polymerase.

Simeprevir (previously known as TMC43) is a competitive, reversible, macrocyclic, noncovalent inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

Grazoprevir (formerly MK-5172; MK5172; trade name: Zepatier‎) is a 2nd generation and selective inhibitor of the Hepatitis C Virus NS3/4A Protease approved by FDA in 2016 for the treatment of hepatitis C (used in combination with elbasvir, an NS5A replication complex inhibitor). It inhibits HCV genotype 1a, 1B, and 4 with IC50 values of 7pM, […]

HZ-1157 is a novel and potent hepatitis C virus (HCV) inhibitor.

Faldaprevir (BI201335; BI-201335) is a novel and potent potent NS3/NS4A protease inhibitor with the potential to be used in the treatment of HCV infection.

Boceprevir (previously known as EBP 520; SCH 503034; trade name: Victrelis) is a novel, orally bioavailable, selective, direct acting inhibitor of hepatitis C virus (HCV) protease with Ki value of 14 nM for NS3 in an enzyme assay and EC90 of 350 nM in cell-based replicon assay. It is an FDA approved drug (trade name: […]

Voxilaprevir (formerly GS-9857; GS9857; trade name: Vosevi) is a hepatitis C virus nonstructural protein (HCV NS) 3/4A protease inhibitor developed by Gilead and approved in 2017 as an anti-HCV drug for use in combination with sofosbuvir and velpatasvir.